Dianthus Therapeutics, Inc. /DE/ DNTH
Pharmaceutical Preparations · CIK 0001690585 · Fiscal year ends 1231
Revenue
$2.04M
Fiscal year ended 2025-12-31Operating income
-$177.93M
Fiscal year ended 2025-12-31Free cash flow
—Unavailable
Fiscal year ended 2025-12-31Valuation, from the filing
| Public float | $599.40M | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|
| Float per share | $13.48 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
|---|
| Float / revenue | 294.4× | A lower bound on the multiple, because affiliate holdings are excluded. |
|---|
| Float / equity | 1.2× | A lower bound on the multiple, because affiliate holdings are excluded. |
|---|
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.
How this compares in its industry
Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported revenue of $2.04M and net income of -$162.34M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Dianthus Therapeutics, Inc. /DE/’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
Dianthus Therapeutics, Inc. /DE/ income by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|
| Revenue | $2.04M | $6.24M | $2.83M | $0 | $0 | $0 | $0 |
|---|
| Cost of revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Gross profit | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Operating income | -$177.93M | -$101.86M | -$48.17M | -$82.97M | -$59.96M | -$35.73M | -$9.27M |
|---|
| Net income | -$162.34M | -$84.97M | -$43.56M | -$76.77M | -$57.52M | -$35.49M | -$9.43M |
|---|
| Research & development | $145.64M | $83.10M | $32.84M | $59.21M | $41.34M | $27.90M | $5.78M |
|---|
| Weighted-average diluted shares | shares 38.62M | shares 33.31M | shares 5.15M | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Pretax income | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Income tax expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
|---|
| Diluted EPS | $-4.20 | $-2.55 | $-8.45 | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Selling, general & administrative | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| General & administrative | $34.33M | $24.99M | $18.16M | $23.76M | $18.62M | $7.83M | $3.49M |
|---|
| Selling & marketing | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Balance
Dianthus Therapeutics, Inc. /DE/ balance by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|
| Cash & equivalents | $51.09M | $22.79M | $132.32M | $65.07M | $58.34M | $51.40M | $4.51M |
|---|
| Total assets | $530.92M | $374.01M | $179.40M | $161.51M | $157.31M | $54.46M | —Unavailable |
|---|
| Current assets | $409.44M | $280.90M | $177.45M | $149.84M | $145.32M | $52.50M | —Unavailable |
|---|
| Total liabilities | $37.52M | $21.53M | $10.54M | $20.32M | $11.66M | $4.14M | —Unavailable |
|---|
| Current liabilities | $30.73M | $18.45M | $9.63M | $14.12M | $10.42M | $4.14M | —Unavailable |
|---|
| Total equity incl. NCI | $493.40M | $352.48M | $168.87M | $141.19M | $145.65M | -$42.12M | -$8.87M |
|---|
| Temporary (mezzanine) equity | —Unavailable | —Unavailable | $0 | $0 | —Unavailable | $92.44M | $17.92M |
|---|
| Inventory | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Accounts receivable | $52.00K | $0 | $294.00K | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Goodwill | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Long-term debt | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Accounts payable | $9.72M | $4.58M | $2.61M | $2.81M | $3.49M | $167.00K | —Unavailable |
|---|
Cash flow
Derived
Dianthus Therapeutics, Inc. /DE/ derived by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|
| Free cash flow | —Unavailable | —Unavailable | —Unavailable | -$60.16M | -$49.56M | -$24.46M | -$6.67M |
|---|
| Gross margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Operating margin | -8739.3% | -1633.7% | -1704.7% | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| FCF margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| SBC / revenue | 1119.5% | 206.8% | 102.6% | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Current ratio | 13.32x | 15.22x | 18.42x | 10.62x | 13.95x | 12.68x | —Unavailable |
|---|
| Revenue YoY growth | -67.3% | 120.6% | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Net margin | -7973.3% | -1362.8% | -1541.2% | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| R&D / revenue | 7153.1% | 1332.9% | 1162.1% | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| CapEx / revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Long-term debt / equity | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Effective tax rate | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DNTH in the interactive workspace to inspect any figure back to its filing.
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.